GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ConvaTec Group PLC (LSE:CTEC) » Definitions » Debt-to-EBITDA

ConvaTec Group (LSE:CTEC) Debt-to-EBITDA : 2.91 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is ConvaTec Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ConvaTec Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £16 Mil. ConvaTec Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £1,020 Mil. ConvaTec Group's annualized EBITDA for the quarter that ended in Dec. 2023 was £357 Mil. ConvaTec Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.91.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ConvaTec Group's Debt-to-EBITDA or its related term are showing as below:

LSE:CTEC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.88   Med: 4.18   Max: 10.64
Current: 2.88

During the past 11 years, the highest Debt-to-EBITDA Ratio of ConvaTec Group was 10.64. The lowest was 2.88. And the median was 4.18.

LSE:CTEC's Debt-to-EBITDA is ranked worse than
71.95% of 435 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs LSE:CTEC: 2.88

ConvaTec Group Debt-to-EBITDA Historical Data

The historical data trend for ConvaTec Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ConvaTec Group Debt-to-EBITDA Chart

ConvaTec Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.39 3.72 3.61 3.82 2.88

ConvaTec Group Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.47 3.96 4.10 3.19 2.91

Competitive Comparison of ConvaTec Group's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, ConvaTec Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ConvaTec Group's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ConvaTec Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ConvaTec Group's Debt-to-EBITDA falls into.



ConvaTec Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ConvaTec Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(16.353 + 1020.443) / 359.845
=2.88

ConvaTec Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(16.353 + 1020.443) / 356.606
=2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


ConvaTec Group  (LSE:CTEC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ConvaTec Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ConvaTec Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ConvaTec Group (LSE:CTEC) Business Description

Traded in Other Exchanges
Address
23 Forbury Road, 3 Forbury Place, Reading, GBR, RG1 3JH
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and continence care are the largest divisions, accounting for 30% and 26% of total revenue, respectively. Ostomy contributes 25% of revenue and infusion sets 19%.

ConvaTec Group (LSE:CTEC) Headlines